TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an announcement.
CARsgen Therapeutics Holdings Ltd. announced the passing of Mr. Bingsen Guo, a non-executive director who had been with the company for over a decade. Mr. Guo played a crucial role in the company’s strategic transformation and development, providing key support during critical business initiatives. His contributions have been instrumental in overcoming challenges and ensuring the company’s steady growth. The board expressed its condolences to Mr. Guo’s family and acknowledged his significant impact on the company’s success.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on the development of innovative CAR-T cell therapies for the treatment of cancer. The company operates in the biopharmaceutical industry and is dedicated to advancing its pipeline of products to address unmet medical needs in the oncology market.
Average Trading Volume: 2,607,231
Technical Sentiment Signal: Hold
Current Market Cap: HK$11.68B
See more data about 2171 stock on TipRanks’ Stock Analysis page.